Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus AG in advanced pancreatic cancer
NCT05969171Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of surufatinib in pancreatic cancer (PC) (2 arms), sponsored by Fudan University. Primary endpoint: Progression-free survival. Started Dec 2023; status: recruiting.
02
Drugs
surufatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05969171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969171.